FDA accepts Endo's harder-to-abuse Opana ER application, with six-month review set
27 June 2011
Nancy Faigen
Please Login to read the full article.
27 June 2011
Nancy Faigen
nancy.faigen@informausa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Acura investors euphoric over US FDA OK of oxycodone painkiller
- BDSI CEO: Shared fentanyl REMS puts Onsolis on level playing field
- US Capitol Capsule: What's in a name? FDA mulls unique versus same for biosimilars
- Collegium collects $22M in venture round for tamper-resistant ER oxycodone product
COMMENT
Other Informa Comment
EVENTS
Today
Le Plaza Hotel, Brussels, Belgium
Today
Diplomat Hotel, Prague, Czech Republic
Today
Business Design Centre, London
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
